Fiona Coats Appointed Chief Marketing Officer at Refeyn

Refeyn, the company behind pioneering mass photometry technologies, is delighted to announce the appointment of Fiona Coats as Chief Marketing Officer, effective from June, 2024. Forming part of Refeyn’s executive team, Fiona will bring with her a wealth of experience from over 25 years in the biotechnology sector. Her extensive background in science, combined with a proven track record of driving growth and innovation, positions her as a respected leader in the life science research market.

Educated in the UK, Fiona Coats holds a Ph.D. in Physiology/Pharmacology and a B.Sc. in Pharmacology, and has successfully leveraged her scientific insights to excel in strategic marketing and drive business expansion. Her career highlights include spearheading revenue growth, crafting cutting-edge go-to-market strategies, and overseeing product management within the competitive life science research arena.

Fiona’s professional journey includes pivotal roles at Biosource International, Meso Scale Diagnostics, ThermoFisher Scientific and more recently at Sartorius, where she has consistently excelled in building brands and expanding market presence. She has managed global teams and budgets with a focus on transformative returns through innovative marketing strategies targeting attractive growth segments. As she takes on the role of Chief Marketing Officer, Fiona’s expertise is expected to drive the company’s growth and solidify its market position. Her dynamic and informed marketing leadership is set to propel the company towards a future of sustained success.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version